/PRPH
PRPH Stock - ProPhase Labs, Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$0.09-14.65%
$0.02 (-14.65%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.1
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+15507.6%upside
Target: $14.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PRPH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.09 – $0.09
TARGET (TP)$14.00
STOP LOSS$0.08
RISK/REWARD1:1434.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.64
52W High$9.35
52W Low$0.08
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $6.77M | $44.38M | $122.65M | $79.04M | $14.51M |
| Gross Profit | $-150,000 | $16.24M | $70.65M | $32.81M | $4.61M |
| Gross Margin | -2.2% | 36.6% | 57.6% | 41.5% | 31.7% |
| Operating Income | $-38,629,000 | $-21,613,000 | $23.59M | $9.80M | $-3,973,000 |
| Net Income | $-53,364,000 | $-16,782,000 | $18.46M | $6.27M | $-2,125,000 |
| Net Margin | -788.2% | -37.8% | 15.1% | 7.9% | -14.6% |
| EPS | $-2.61 | $-0.98 | $1.17 | $0.41 | $-0.20 |
Company Overview
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
PRPHBeat Rate
37%
Last 19 quarters
Avg Surprise
-78.3%
EPS vs Estimate
Beats / Misses
7/12
Last 12 quarters
Latest EPS
$-0.16
Q4 2025
EPS Surprise History
Q1 24
-96.2%
$-0.51vs$-0.26
Q2 24
+75.0%
$-0.07vs$-0.28
Q3 24
-312.5%
$-0.33vs$-0.08
Q4 24
-12.9%
$-0.35vs$-0.31
Q1 25
-112.5%
$-0.51vs$-0.24
Q2 25
+33.3%
$-0.12vs$-0.18
Q3 25
+26.7%
$-0.11vs$-0.15
Q4 25
-45.5%
$-0.16vs$-0.11
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 18, 2026 | — | — | — | — |
Q4 2025 | Nov 19, 2025 | $-0.11 | $-0.16 | -45.5% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-0.15 | $-0.11 | +26.7% | ✓ BEAT |
Q2 2025 | May 20, 2025 | $-0.18 | $-0.12 | +33.3% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-0.24 | $-0.51 | -112.5% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.31 | $-0.35 | -12.9% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.08 | $-0.33 | -312.5% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.28 | $-0.07 | +75.0% | ✓ BEAT |
Q1 2024 | Mar 28, 2024 | $-0.26 | $-0.51 | -96.2% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.20 | $-0.30 | -50.0% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.14 | $-0.20 | -42.9% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.09 | $0.03 | +133.3% | ✓ BEAT |
Q1 2023 | Mar 28, 2023 | $-0.01 | $-0.08 | -580.3% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $0.19 | $0.06 | -68.4% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $0.18 | $0.40 | +122.2% | ✓ BEAT |
Q2 2022 | May 13, 2022 | $0.39 | $0.68 | +74.4% | ✓ BEAT |
Q1 2022 | Mar 30, 2022 | $0.36 | $0.44 | +22.2% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | $0.07 | $-0.26 | -471.4% | ✗ MISS |
Q3 2021 | Aug 13, 2021 | $0.19 | $-0.09 | -147.4% | ✗ MISS |
Q2 2021 | May 13, 2021 | $0.35 | $0.23 | -34.3% | ✗ MISS |
Latest News
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Dec 20, 2025, 12:50 AM
Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Dec 19, 2025, 12:25 PM
ProPhase Labs Signs Non-Binding LOI For Proposed Reverse Merger With Advanced Biological Laboratories, With ABL Expected To Own About 76% And ProPhase Considering Up To $10M Special Dividend
📈 PositiveBenzinga•Dec 19, 2025, 12:06 PM
Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Dec 19, 2025, 11:55 AM
ProPhase Labs Approves 1-For-10 Reverse Stock Split, Effective December 22, 2025
➖ NeutralBenzinga•Dec 12, 2025, 04:48 PM
ALT5 Sigma Announces Executive Changes, Jonathan Hugh CFO And Acting CEO To Depart, Without Cause; COO Ron Pitters Announces Departure; Tony Isaac Named Acting CEO, Steven Plumb Appointed CFO
📉 NegativeBenzinga•Nov 26, 2025, 10:27 PM•Also: , ,
ProPhase Labs Says On Nov 21, Received Confirmation From Avtech Agreeing To Continue Its Forbearance Under Co's Existing Equipment Lease; Under Avtech's Updated Payment Schedule, Co To Make Weekly Payments Beginning Nov 28, Until Outstanding Past-Due Amounts Are Current
➖ NeutralBenzinga•Nov 25, 2025, 10:07 PM
ProPhase Labs Says Aware That Civil Action Pending In The U.S. District Court For The Eastern District Of New York Has Been Unsealed; Denies Wrongdoing, Maintains That Its Laboratory And Diagnostic Operations Follow Compliance Standards; Expects No Impact On Operations From Unsealed Matter; Co To Vigorously Defend Matter Once Formally Served
➖ NeutralBenzinga•Nov 25, 2025, 10:05 PM
ProPhase Labs Is In Discussions For Strategic Initiative To Realize Significant Underlying Value In The Company; Announced It Is In M&A Related Discussions Not Connected To A Crypto Treasury Strategy
📈 PositiveBenzinga•Nov 19, 2025, 01:17 PM
ProPhase Labs Q3 EPS $(0.16) Misses $(0.11) Estimate, Sales $883.000K Miss $5.690M Estimate
📉 NegativeBenzinga•Nov 19, 2025, 01:16 PM
Prophase Labs Announces Publication Of Peer-Reviewed Study In Clinical And Translational Gastroenterology Conducted With The Mayo Clinic, Showing 100% Sensitivity And Strong Predictive Accuracy For Progression To Esophageal Cancer
📈 PositiveBenzinga•Oct 29, 2025, 12:34 PM
ProPhase Labs Announces Study Validating Its BE-Smart Esophageal Test Has Been Accepted for Publication In 'Clinical Gastroenterology and Hepatology'
📈 PositiveBenzinga•Oct 22, 2025, 11:31 AM
ProPhase Labs Entered Into Sales Agreement With Westpark Capital Relating To Shares Of Common Stock Offered By Prospectus Supplement; May Offer And Sell Shares Of Common Stock From Time To Time Up To $4.3M
➖ NeutralBenzinga•Oct 15, 2025, 09:31 PM•Also:
Three Of ProPhase Labs' COVID-19 Testing Laboratories Filed For Chapter II
📉 NegativeBenzinga•Sep 23, 2025, 12:08 PM
ProPhase Enters Agreement Relating To Potential Advisory Services As Management Explores Crypto Treasury Strategy
➖ NeutralBenzinga•Sep 22, 2025, 12:15 PM
ProPhase Labs Says On Sept. 12 Entered Strategic Advisory and Private Placement Agreement With ThinkEquity, Pursuant To Which ThinkEquity Will Serve As Advisor In Connection With Digital Asset Strategy And Proposed Private Placement Of ~$6M Of Co.'s Securities
📈 PositiveBenzinga•Sep 18, 2025, 08:21 PM
ProPhase Labs shares are trading lower. The company moved forward with its strategic initiatives, including a significant increase in authorized shares to 1 billion.
📉 NegativeBenzinga•Sep 12, 2025, 03:34 PM
ProPhase Labs Shareholders Approve Strategic Expansion, Including Increase In Authorized Shares To 1B
➖ NeutralBenzinga•Sep 12, 2025, 12:12 PM
ProPhase Labs Posts Narrower Q2 Loss
📈 PositiveThe Motley Fool•Aug 13, 2025, 01:19 PM
Frequently Asked Questions about PRPH
What is PRPH's current stock price?
ProPhase Labs, Inc. (PRPH) is currently trading at $0.09 per share. The stock has moved -14.65% today.
What is the analyst price target for PRPH?
The average analyst price target for PRPH is $14.00, based on 1 analyst.
What sector is ProPhase Labs, Inc. in?
ProPhase Labs, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is PRPH's market cap?
ProPhase Labs, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does PRPH pay dividends?
No, ProPhase Labs, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADAP
Adaptimmune Therapeutics plc
$0.05
Mkt Cap: $0.0B
AEMD
Aethlon Medical, Inc.
$2.86
Mkt Cap: $0.0B
ALUR
Allurion Technologies Inc.
$1.47
Mkt Cap: $0.0B
AYTU
Aytu BioPharma, Inc.
$2.55
Mkt Cap: $0.0B
BFRI
Biofrontera Inc.
$0.77
Mkt Cap: $0.0B
CODX
Co-Diagnostics, Inc.
$0.26
Mkt Cap: $0.0B
ERNA
Ernexa Therapeutics Inc.
$1.31
Mkt Cap: $0.0B
LNAI
Lunai Bioworks Inc.
$1.05
Mkt Cap: $0.0B
SBFM
Sunshine Biopharma, Inc.
$1.39
Mkt Cap: $0.0B
TXMD
TherapeuticsMD, Inc.
$1.70
Mkt Cap: $0.0B
Explore stocks similar to PRPH for comparison